Senhwa Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jin-Ding Huang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2yrs
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

Mar 18

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

Jan 19

CEO

Jin-Ding Huang

3.1yrs

Görev süresi

Dr. Jin-Ding Huang, PhD, serves as Chief Executive Officer at Senhwa Biosciences, Inc. since 2022 and serves as its President and served as its General Manager until January 01, 2025 and served as its Dire...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Sarah Chang	Executive VP	10.9yrs	NT$8.76m	Veri yok
Jin-Ding Huang	President & CEO	3.1yrs	Veri yok	Veri yok
Joanne Lo	Acting Chief Operating Officer & Business Development Director	2yrs	Veri yok	Veri yok
Jocelyn Lee	Director of Regulatory & Legal Affairs	1.1yrs	Veri yok	Veri yok
Jason Huang	Chief Medical Officer	less than a year	Veri yok	Veri yok

2.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 6492 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ting-Wu Hu	Chairman	12.3yrs	Veri yok	2.04% NT$ 77.1m
Chia-Hung Lee	Supervisor	9.9yrs	Veri yok	Veri yok
Jo Shen	Director	2.1yrs	Veri yok	Veri yok
Chi-Hai Lin	Supervisor	8.7yrs	Veri yok	Veri yok
Jien-Fu Chen	Director	7.7yrs	Veri yok	Veri yok
Yeu-Chuyr Chang	Independent Director	9.9yrs	NT$160.00k	Veri yok
Eric Hu	Supervisor	7.7yrs	Veri yok	Veri yok
Yung-Lin Ma	Independent Director	4.7yrs	NT$80.00k	Veri yok
Tong-Young Lee	Independent Director	4.7yrs	NT$80.00k	Veri yok
Yiu-Lian Fong	Director	less than a year	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 6492 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/02 03:24
Gün Sonu Hisse Fiyatı	2025/01/22 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Senhwa Biosciences, Inc. 2 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yenya Kuo	Capital Securities Corporation
Jane Jiang	Yuanta Research

Senhwa Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Senhwa Biosciences, Inc. Announces Retirement of Jin-Ding Huang as General Manager

Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Senhwa Biosciences, Inc. Announces Retirement of Jin-Ding Huang as General Manager

New minor risk - Share price stability

Third quarter 2024 earnings released: NT$0.91 loss per share (vs NT$0.84 loss in 3Q 2023)

Senhwa Biosciences Announces First Patient Dosed in the Phase I/Ii Study of Silmitasertib in Children and Young Adults with Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. Announces US FDA Issues Study May Proceed Letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the Us National Cancer Institute

Senhwa Biosciences, Inc. Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors Sponsored by NCI

US FDA Grants RPD Designation to Senhwa Biosciences Silmitasertib for Pediatric Neuroblastoma

Senhwa Biosciences, Inc. Announces Phase Ib Expansion Study Abstract of Cx-5461 in Solid Tumours and Brca2 And/Or Palb2 Mutations

Senhwa Biosciences, Inc. Announces Promotion of Sarah Chang as Executive Vice President, Effective August 9, 2024

Senhwa Biosciences, Inc. Receives US FDA Study May Proceed Letter for the Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors

Senhwa Biosciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Senhwa Biosciences Announces IND Submission to US FDA for the Phase I/II Study of Silmitasertib in Children /Dearyoung Adults with Relapsed Refractory Solid Tumors

First quarter 2024 earnings released: NT$0.71 loss per share (vs NT$0.82 loss in 1Q 2023)

Senhwa Biosciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Senhwa Biosciences, Inc., Annual General Meeting, Jun 21, 2024

Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$3.92 loss in FY 2022)

Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19

Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia (Cap) Associated with Viral Infection

Third quarter 2023 earnings released: NT$0.84 loss per share (vs NT$0.93 loss in 3Q 2022)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19

New minor risk - Share price stability

Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection

First half 2023 earnings released: NT$1.54 loss per share (vs NT$1.96 loss in 1H 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.93 loss per share (vs NT$0.97 loss in 3Q 2021)

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer

First half 2022 earnings released: NT$1.96 loss per share (vs NT$1.78 loss in 1H 2021)

Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC

No longer forecast to breakeven

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to NT$143

Less than half of directors are independent

Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting

Forecast breakeven date pushed back to 2022

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues miss analyst expectations

Senhwa Biosciences, Inc. Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and Other HR Gene Mutations

Us Food and Drug Administration Grants Orphan Drug Designation to Senhwa Biosciences, Inc. for Silmitasertib, A Highly Selective Inhibitor of Casein Kinase 2 (Ck2)

Third quarter 2021 earnings released: NT$0.97 loss per share (vs NT$1.53 loss in 3Q 2020)

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase 1B Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations

Senhwa Biosciences Announces Dose Escalation Initiation of the Phase I Trial of Pidnarulex as a Treatment for Advanced Hematological Malignancies

Senhwa's Silmitasertib Receives US FDA Fast Track Designation for the Treatment of Recurrent Sonic Hedgehog Driven Medulloblastoma

Senhwa Announces Ind Submission to India's Cdsco of A Phase II Clinical Study for Silmitasertib as A Potential Covid-19 Treatment

First quarter 2021 earnings released: NT$1.02 loss per share (vs NT$1.13 loss in 1Q 2020)

Full year 2020 earnings released: NT$4.49 loss per share (vs NT$5.26 loss in FY 2019)

Analysts Are Optimistic We'll See A Profit From Senhwa Biosciences, Inc. (GTSM:6492)

New 90-day low: NT$162

Does This Valuation Of Senhwa Biosciences, Inc. (GTSM:6492) Imply Investors Are Overpaying?

New 90-day low: NT$172

Senhwa Biosciences Presents Positive Cholangiocarcinoma Data

Senhwa Announces the First Patient Enrolled in an Investigator Initiated Trial Of Silmitasertib as a Treatment for COVID-19

Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations

Earnings beat expectations

Third quarter 2020 earnings released: NT$1.52 loss per share

CARE GA Receives Study May Proceed Letter from US FDA to Initiate Phase II Clinical Trial of Senhwa's Silmitasertib in COVID-19 Patients

Senhwa Announces Multiple INDApplication Submissions to U.S. FDA for Silmitasertib as A Potential Treatment for COVID-19

New 90-day high - NT$181

First half earnings released

New 90-day high - NT$180

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Şirket Analizi ve Finansal Veri Durumu